SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?


To: Biomaven who wrote (1342)7/14/2000 6:13:13 AM
From: NeuroInvestment  Read Replies (2) | Respond to of 52153
 
My recollection is that NTII receives 8% of the royalties for AD, 75% of the royalties for neuropathic pain and ADIS-dementia. If Forest is paying in the range of 20% royalties on memantine sales, this would translate into 1.6% to NTII for AD, 15% on the other indications. Or almost exactly what you postulated. The undisclosed factor is the FRX royalty rate, but 20% is a ballpark estimate.

NeuroInvestment (www.neuroinvestment.com)